212 related articles for article (PubMed ID: 29270487)
1. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.
Vincenti F; Fervenza FC; Campbell KN; Diaz M; Gesualdo L; Nelson P; Praga M; Radhakrishnan J; Sellin L; Singh A; Thornley-Brown D; Veronese FV; Accomando B; Engstrand S; Ledbetter S; Lin J; Neylan J; Tumlin J;
Kidney Int Rep; 2017 Sep; 2(5):800-810. PubMed ID: 29270487
[TBL] [Abstract][Full Text] [Related]
2. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.
Trachtman H; Fervenza FC; Gipson DS; Heering P; Jayne DR; Peters H; Rota S; Remuzzi G; Rump LC; Sellin LK; Heaton JP; Streisand JB; Hard ML; Ledbetter SR; Vincenti F
Kidney Int; 2011 Jun; 79(11):1236-43. PubMed ID: 21368745
[TBL] [Abstract][Full Text] [Related]
3. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety.
Campbell KN; Gesualdo L; Murphy E; Rheault MN; Srivastava T; Tesar V; Komers R; Trachtman H
Kidney Med; 2024 Jun; 6(6):100833. PubMed ID: 38831932
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children.
Lieberman KV; Tejani A
J Am Soc Nephrol; 1996 Jan; 7(1):56-63. PubMed ID: 8808110
[TBL] [Abstract][Full Text] [Related]
5. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Spino C; Kaskel FJ; Friedman A; Moxey-Mims MM; Fine RN; Gassman JJ; Kopp JB; Walsh L; Wang R; Gipson DS
Am J Kidney Dis; 2021 Feb; 77(2):216-225. PubMed ID: 32791086
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.
Cattran DC; Appel GB; Hebert LA; Hunsicker LG; Pohl MA; Hoy WE; Maxwell DR; Kunis CL
Kidney Int; 1999 Dec; 56(6):2220-6. PubMed ID: 10594798
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy.
Tumlin J; Galphin C; Santos R; Rovin B
Kidney Int Rep; 2017 Sep; 2(5):924-932. PubMed ID: 29270498
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis.
Chiou YY; Lee YC; Chen MJ
Curr Med Res Opin; 2017 Aug; 33(8):1389-1399. PubMed ID: 28436233
[TBL] [Abstract][Full Text] [Related]
9. Primary FSGS in Nephrotic Adults: Clinical Profile, Response to Immunosuppression and Outcome.
Bagchi S; Agarwal S; Kalaivani M; Bhowmik D; Singh G; Mahajan S; Dinda A
Nephron; 2016; 132(2):81-5. PubMed ID: 26799973
[TBL] [Abstract][Full Text] [Related]
10. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H;
N Engl J Med; 2023 Dec; 389(26):2436-2445. PubMed ID: 37921461
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.
Han KH; Kim SH
Biomed Res Int; 2016; 2016():3053706. PubMed ID: 27195285
[TBL] [Abstract][Full Text] [Related]
12. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H; Nelson P; Adler S; Campbell KN; Chaudhuri A; Derebail VK; Gambaro G; Gesualdo L; Gipson DS; Hogan J; Lieberman K; Marder B; Meyers KE; Mustafa E; Radhakrishnan J; Srivastava T; Stepanians M; Tesar V; Zhdanova O; Komers R;
J Am Soc Nephrol; 2018 Nov; 29(11):2745-2754. PubMed ID: 30361325
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.
Joy MS; Gipson DS; Powell L; MacHardy J; Jennette JC; Vento S; Pan C; Savin V; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Am J Kidney Dis; 2010 Jan; 55(1):50-60. PubMed ID: 19932542
[TBL] [Abstract][Full Text] [Related]
14. Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study.
Raina R; Krishnappa V; Sanchez-Kazi C; Quiroga A; Twombley KE; Mathias R; Lo M; Chakraborty R; Mahesh S; Steinke J; Bunchman T; Zaritsky J
Front Pediatr; 2019; 7():454. PubMed ID: 31850285
[No Abstract] [Full Text] [Related]
15. Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
Trachtman H; Diva U; Murphy E; Wang K; Inrig J; Komers R
Kidney Int Rep; 2023 Oct; 8(10):2017-2028. PubMed ID: 37850006
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis.
Gipson DS; Hladunewich MA; Lafayette R; Sedor JR; Rovin BH; Barbour SJ; McMahon A; Jennette JC; Nachman PH; Willette RN; Paglione M; Gao F; Ross Terres JA; Vallow S; Holland MC; Thorneloe KS; Sprecher DL
Kidney Int Rep; 2020 Aug; 5(8):1228-1239. PubMed ID: 32775822
[TBL] [Abstract][Full Text] [Related]
17. Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis.
Komers R; Diva U; Inrig JK; Loewen A; Trachtman H; Rote WE
Kidney Int Rep; 2020 Apr; 5(4):494-502. PubMed ID: 32274453
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial.
Ren H; Shen P; Li X; Pan X; Zhang W; Chen N
Am J Nephrol; 2013; 37(1):84-90. PubMed ID: 23343906
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).
Komers R; Gipson DS; Nelson P; Adler S; Srivastava T; Derebail VK; Meyers KE; Pergola P; MacNally ME; Hunt JL; Shih A; Trachtman H
Kidney Int Rep; 2017 Jul; 2(4):654-664. PubMed ID: 29142983
[TBL] [Abstract][Full Text] [Related]
20. Focal segmental glomerulosclerosis, excluding atypical lesion, is a predictor of renal outcome in patients with membranous nephropathy: a retrospective analysis of 716 cases.
He HG; Wu CQ; Ye K; Zeng C; Huang YY; Luo SW; Yin W; Ye QR; Peng XM
BMC Nephrol; 2019 Aug; 20(1):328. PubMed ID: 31438882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
